Owing to their small size, their demonstrated activity in trastuzumab-resistant cells/tumours and their ability to target multiple EGFR family receptors, TKIs represent attractive therapeutic agents to treat residual disease after dual antibody-based HER2-targeting therapy [11]. The gene discussed is ERBB2; the disease is neoplasm.